Skip to main content
. Author manuscript; available in PMC: 2016 Feb 2.
Published in final edited form as: Hypertension. 2014 Dec 1;65(2):430–439. doi: 10.1161/HYPERTENSIONAHA.114.04439

Figure 4. In vivo siRNA knockdown of PCT (PCYT1b) attenuated systolic pressure, proteinuria, placental and kidney damage, sFlt-1 production.

Figure 4

(A) Confirmation of knockdown is shown by qRT-PCR on placental lysates (n=5). Administration of nanoparticle-encapsulated siRNA for PCYT1b with CRP on E13/14 reduced the mean systolic pressure of the pregnant mice. * = p < 0.05 (B) Cotreatment of PCYT1b siRNA reduced microalbuminuria/creatinine ratio. * = p < 0.05 (C) Glomerular damage was significantly attenuated by coadministration of PCYT1b siRNA as shown by H&E stained renal sections. (100x magnification; scale bar = 50 μm) (D) Placental damage was attenuated by cotreatment with PCYT1b siRNA, as indicated by reduction of placental calcifications and scarring shown on H&E placental sections. (20x magnification; scale bar = 200 μm) (E) Histologic scoring of glomerular damage based on double-blinded scoring criteria (n=10 fields per kidney; 7 animals). * = p < 0.05 (F) Quantification of placental calcifications based on blinded image analysis (n=10 fields per placenta; 7 animals). * = p < 0.05 (G) CRP induced sFlt-1 production was significantly attenuated in pregnant mice with coadministration of SB222200 or siRNA for PCYT1b. * = p < 0.05